newsfilter
← Earnings
Earnings Releases·

Spero Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported zero revenue for Q3 2026 versus $5.4 million in Q3 2025; net loss widened to $44.3 million (vs. $7.4 million) driven by a $35 million upfront payment to Innovent Biologics, resulting in diluted net loss per share of $0.76.
  • Secured exclusive worldwide rights (excluding Greater China) to SP001 via a July 2026 in-licensing agreement and closed a $105 million non-recourse royalty financing, leaving $107.9 million in cash to fund operations through the second half of 2029.
  • Plans to initiate a Phase 2 study for SP001 in IgG4-related disease in Q2 2027, supported by recent appointments of a new Chief Medical Officer, Chief Regulatory and Quality Officer, and a new Board Director.
Company
SPERO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology